type2 diabetes mellitus
Conditions
Interventions
Dose of sitaglyptin increased from 50mg/d to 100mg/d (3-month administration)
Glimepiride 1m/d add to sitaglyptin 50mg/d (3-month administration)
Acarbose 300mg/d or voglibose 0.6mg/d add to sitaglypt
Sponsors
Department of Internal Medicine, Graduate School of Medical Science, Kanazawa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Diabetic patients who administrated sitaglyptin 50mg/d for 3 months or more, and still poor control of plasma glucose.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women 2. Diabetes mellitus patients with unstable glycemic control whose HbA1c is more than 8.0%. Or complicated with diabetic nephropathy more than stage3. 3. Patient who is intolerate or allergic againts sitaglyptin, glimepiride, acarbose or voglibose 4. Patient who has kidney or liver dysfunction 5. Type 1 diabetes mellitus 6. Patient who suffered from ketoacidosis or diabetic coma during 3 months. Or patient who has a history of deep coma. 7. Patient who has a severe infection, an operation, or severe injury.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| glucose control | — |
Secondary
| Measure | Time frame |
|---|---|
| endothelial function, oxidative stress | — |
Countries
Japan
Contacts
Public ContactYoshiyu Takeda
Kanazawa University Hospital Department of Endocrinology and Metabolism
Outcome results
None listed